Compare NSSC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | PGEN |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | NSSC | PGEN |
|---|---|---|
| Price | $37.16 | $4.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $48.17 | $8.33 |
| AVG Volume (30 Days) | 379.4K | ★ 4.9M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | $181,621,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $13.63 | $1,115.92 |
| Revenue Next Year | $10.05 | $81.04 |
| P/E Ratio | $53.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.44 | $1.40 |
| 52 Week High | $47.61 | $5.47 |
| Indicator | NSSC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 64.17 |
| Support Level | $34.77 | $3.96 |
| Resistance Level | $38.07 | $5.06 |
| Average True Range (ATR) | 1.15 | 0.29 |
| MACD | 0.45 | 0.10 |
| Stochastic Oscillator | 69.91 | 97.39 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.